You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Partially platinum sensitive

Showing 1 - 25 of 6,531
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Ovarian Cancer Trial in Pittsburgh (CPI-0209, carboplatin)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Pittsburgh, Pennsylvania
    Magee-Womens Research Institute / UPMC Magee Womens Hospital
Jul 3, 2023

Ovarian Cancer, Malignant Tumor of Uterus Trial in New York (Sacituzumab, Cisplatin)

Not yet recruiting
  • Ovarian Cancer
  • Malignant Neoplasm of Uterus
  • New York, New York
    Icahn School of Medicine at Mount Sinai Division of Hematology a
Sep 14, 2023

Metastatic Breast Cancer Trial in Shanghai (Vinorelbine, DDP)

Recruiting
  • Metastatic Breast Cancer
  • Shanghai, China
    Fudan University Cancer Hospital
Apr 19, 2022

Relapsed Ovarian Cancer Trial (Fluzoparib, Apatinib)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Oct 7, 2023

Platinum-Sensitive Biliary Tract Cancer Trial (Cisplatin, Gemcitabine, Oxaliplatin)

Withdrawn
  • Platinum-Sensitive Biliary Tract Cancer
  • (no location specified)
May 27, 2022

Hormone Sensitive Metastatic Prostate Cancer, DNA Damage Repair Deficiency, Chemo Effect Trial in Nanjing (Docetaxel,

Recruiting
  • Hormone Sensitive Metastatic Prostate Cancer
  • +3 more
  • Nanjing, Jiangsu, China
    Department of Urology, Drum Tower Hospital, Medical School of Na
Jul 13, 2022

Ovarian Cancer Trial (Aribulin;carboplatin;bevacizumab)

Not yet recruiting
  • Ovarian Cancer
  • (no location specified)
Jul 20, 2023

Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer Trial in Los Angeles (Simvastatin 40mg)

Recruiting
  • Recurrent Ovarian Cancer
  • Platinum-sensitive Ovarian Cancer
  • Simvastatin 40mg
  • Los Angeles, California
    Cedars Sinai Medical Center
Apr 21, 2022

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • New Orleans, Louisiana
  • +3 more
Dec 16, 2022

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)

Not yet recruiting
  • High Grade Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 11, 2022

Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)

Not yet recruiting
  • Ovary Cancer
  • +2 more
  • Aurora, Colorado
    University of Colorado Hospital
May 30, 2023

Recurrent Ovarian Cancer Trial in Shanghai (Fuzuloparib Combination with Bevacizumab)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • Fuzuloparib Combination with Bevacizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Cente
Apr 14, 2023

Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemo, Platinum Sensitive Trial in China,

Active, not recruiting
  • Relapsed Ovarian Cancer
  • +2 more
  • Olaparib 300mg tablets
  • Beijing, China
  • +24 more
Dec 5, 2022

Platinum Sensitive Ovarian Cancer, Ovarian Cancer Trial in United States (FRa peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF)

Terminated
Has Results
  • Platinum Sensitive Ovarian Cancer
  • Ovarian Cancer
  • FRĪ± peptide plus Adjuvant (GM-CSF)
  • Adjuvant (GM-CSF) Alone
  • Birmingham, Alabama
  • +17 more
Nov 21, 2022

Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma Trial in United States (ribociclib, Paclitaxel, Carboplatin)

Completed
  • Ovarian Cancer
  • +2 more
  • Ann Arbor, Michigan
  • +7 more
Sep 1, 2022

Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer Trial (Carboplatin)

Not yet recruiting
  • Ovarian Cancer
  • +6 more
  • (no location specified)
Oct 27, 2022

Ovarian Cancer Trial in Manchester (Olaparib, Cediranib, Platinum-based Chemotherapy)

Completed
  • Ovarian Cancer
  • Manchester, United Kingdom
    The Christie NHS Foundation Trust
Feb 4, 2022

Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV Trial in Seoul (Oregovomab, Bevacizumab,

Recruiting
  • Ovarian Cancer by FIGO Stage
  • +2 more
  • Oregovomab
  • +3 more
  • Daegu, Korea, Republic of
  • +5 more
Oct 20, 2022

Prostate Adenocarcinoma Trial in Philadelphia (Niraparib Pill)

Recruiting
  • Prostate Adenocarcinoma
  • Niraparib Pill
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Mar 29, 2022

Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer Trial in Durham, Oklahoma

Recruiting
  • Recurrent Ovarian Cancer
  • +6 more
  • Durham, North Carolina
  • +2 more
Jul 26, 2022

Relapsed Ovarian Cancer Trial (Fluzoparib+Apatinib, Fluzoparib Monotherapy)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Jul 27, 2022

Urothelial Carcinoma Trial in France (Talazoparib + Avelumab)

Recruiting
  • Urothelial Carcinoma
  • Talazoparib + Avelumab
  • Angers, France
  • +13 more
Aug 9, 2022

Carcinoma, Ovarian Epithelial Trial in Hidaka (pembrolizumab, olaparib, bevacizumab)

Recruiting
  • Carcinoma, Ovarian Epithelial
  • pembrolizumab
  • +5 more
  • Hidaka, Saitama, Japan
    Saitama Medical Uiversity International Medical Center
Apr 25, 2022

Ovarian Cancer Trial in Chongqing (fluzopanib and bevacizumab)

Recruiting
  • Ovarian Cancer
  • fluzopanib and bevacizumab
  • Chongqing, Chongqing, China
    Chongqing Cancer Hospital
Sep 19, 2022

PD-1 Blockade Plus Platinum-based Chemotherapy in EGFR Sensitive

Completed
  • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 9, 2022